WSJ.com - U.S. Home
WSJ.com - U.S. HomeBIOGEN AND ELAN PULLED their promising new multiple-sclerosis treatment Tysabri from the market following a patient's death. 11:18 p.m.
Is it possible that this could be a trend? Similar to the Vioxx
Recalls of last year, this is certainly some interesting pharmaceutical news.